AI Summary
This grant opportunity, PAR-25-210, focuses on enhancing mechanistic research on precision probiotic therapies. It is an R33 Clinical Trial Optional grant, and the funding opportunity is associated with CFDA numbers 93.866, 93.313, 93.393, 93.213, and 93.121.